Nutex Health (NASDAQ:NUTX) Reaches New 52-Week High After Analyst Upgrade

Nutex Health Inc. (NASDAQ:NUTX)’s share price reached a new 52-week high during mid-day trading on Tuesday after Maxim Group raised their price target on the stock from $100.00 to $225.00. Maxim Group currently has a buy rating on the stock. Nutex Health traded as high as $184.28 and last traded at $176.21, with a volume of 192685 shares. The stock had previously closed at $174.71.

Separately, Benchmark increased their price objective on shares of Nutex Health from $150.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday, May 15th.

Insider Buying and Selling at Nutex Health

In other news, CFO Jon Christian Bates acquired 1,000 shares of the company’s stock in a transaction on Tuesday, April 8th. The shares were bought at an average cost of $81.81 per share, with a total value of $81,810.00. Following the transaction, the chief financial officer now owns 4,888 shares in the company, valued at approximately $399,887.28. This trade represents a 25.72% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 38.52% of the company’s stock.

Institutional Investors Weigh In On Nutex Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in Nutex Health by 6,590.3% during the 4th quarter. Bank of America Corp DE now owns 2,074 shares of the company’s stock worth $66,000 after acquiring an additional 2,043 shares in the last quarter. OMERS ADMINISTRATION Corp raised its stake in Nutex Health by 28.8% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 9,400 shares of the company’s stock worth $442,000 after acquiring an additional 2,100 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Nutex Health by 17.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 18,119 shares of the company’s stock worth $852,000 after acquiring an additional 2,748 shares in the last quarter. Geode Capital Management LLC raised its stake in Nutex Health by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 34,125 shares of the company’s stock worth $1,082,000 after acquiring an additional 3,826 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft raised its stake in Nutex Health by 64.6% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 10,700 shares of the company’s stock worth $503,000 after acquiring an additional 4,200 shares in the last quarter. 5.32% of the stock is currently owned by institutional investors and hedge funds.

Nutex Health Price Performance

The company’s 50 day moving average is $109.34 and its 200 day moving average is $64.30. The company has a current ratio of 1.77, a quick ratio of 1.74 and a debt-to-equity ratio of 3.36. The stock has a market capitalization of $940.65 million, a price-to-earnings ratio of -18.00 and a beta of -0.10.

Nutex Health (NASDAQ:NUTX) last issued its quarterly earnings data on Tuesday, May 13th. The company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $2.71. Nutex Health had a negative net margin of 14.09% and a negative return on equity of 51.27%. The company had revenue of $211.79 million for the quarter, compared to the consensus estimate of $81.09 million.

About Nutex Health

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.